<?xml version="1.0" encoding="UTF-8"?>
<Label drug="metrolotion" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  In a controlled clinical trial, safety data from 141 patients who used MetroLotion  (r)  Topical Lotion (n=71), or the lotion vehicle (n=70), twice daily and experienced a local cutaneous adverse event which may or may not have been related to the treatments include: local allergic reaction, MetroLotion  (r)  Topical Lotion 2 (3%), lotion vehicle 0; contact dermatitis, MetroLotion  (r)  Topical Lotion 2 (3%), lotion vehicle 1 (1%); pruritus, MetroLotion  (r)  Topical Lotion 1 (1%), lotion vehicle 0; skin discomfort (burning and stinging), MetroLotion  (r)  Topical Lotion 1 (1%), lotion vehicle 2 (3%); erythema, MetroLotion  (r)  Topical Lotion 4 (6%), lotion vehicle 0; dry skin, MetroLotion  (r)  Topical Lotion 0, lotion vehicle 1 (l%); and worsening of rosacea, MetroLotion  (r)  Topical Lotion 1 (1%), lotion vehicle 7 (10%).



 The following additional adverse experiences have been reported with the topical use of metronidazole: skin irritation, transient redness, metallic taste, tingling or numbness of extremities, and nausea.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
